PTK 2015 Banner 
2015 Peptalk M Banner 

 SHORT COURSE 10: TRANSIENT PROTEIN PRODUCTION
IN MAMMALIAN CELLS

Tuesday, January 20 | 5:00-8:00 pm  

This short course introduces both the fundamental concepts and technologies needed to establish transient protein production in mammalian cells. This allows for the rapid generation, purification and characterization of milligram-to-gram quantities of secreted or intracellular recombinant proteins for therapeutic, functional and structural studies. The course combines instruction and case studies in an interactive environment.

What You Will Learn: 

  • An In-Depth Introduction to Mammalian Transient Expression Systems
  • Examination of the Key Elements Necessary for the Establishment of a Mammalian Transient Production System
  • Scaling Transient Protein Production to Accommodate a Wide Variety of Early Discovery Studies and Applications
  • Optimizing the Transient Protein Production Process
  • Tools and Strategies for Purification and Evaluation of Transiently Expressed Proteins

Who Should Attend?
Scientists interested in setting up a rapid and robust mammalian expression process to produce milligram to gram quantities of recombinant protein. 

 

Instructors:
Richard Altman, MS, Research Scientist, Molecular Sciences, Alexion Pharmaceuticals
Henry C. Chiou, Ph.D., Associate Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific
Dominic Esposito, Ph.D., Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. 

Speaker Biographies:

Richard Altman Richard Altman, MS, Research Scientist, Molecular Sciences, Alexion Pharmaceuticals

Mr. Altman has over 23 years of experience working in the pharmaceutical industry. For the past two years, he has worked in the Molecular Sciences group at Alexion Pharmaceuticals developing antibody and non-antibody biologics. Prior to Alexion, he worked for several pharmaceutical companies on the cloning, expression, purification and characterization of recombinant proteins. This work supported both high-throughput screening and protein therapeutic efforts. In addition, he has been involved in the generation of transgenic animal models and their characterization. Mr. Altman received his MS degree from the University of Pittsburgh School of Medicine in the Department of Molecular Biology and Biochemistry.

Henry C. Chiou Henry C. Chiou, Ph.D., Associate Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific

Dr. Chiou has over 15 years of experience working on development of mammalian protein expression systems and transfection reagents. For the past nine years he has worked as a principal scientist and now in product development and portfolio management for Life Technologies, now part of Thermo Fisher Scientific. He has led the development efforts on a number of products, including the FreeStyle™ transient expression systems, Lipofectamine™ LTX and Lipofectamine™ RNAiMAX. Prior to Life Technologies, he worked for several biotech companies on biotherapeutic gene delivery systems. Dr. Chiou received his doctorate from Harvard University and completed a postdoctoral fellowship at the University of Pennsylvania.

Dominic EspositoDominic Esposito, Ph.D., Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. 

Dr. Esposito is currently the Director of the Protein Expression Laboratory (PEL) at the Frederick National Laboratory for Cancer Research. The PEL is currently focused on producing Ras and Ras-related proteins for the National Cancer Institute’s RAS Initiative. These proteins are being used for a wide-ranging attack on mutant Ras genes including structural biology, biophysics and development of screens and assays for drug discovery. In addition, the PEL still assists in the generation of proteins of interest to investigators in the intramural program of the NCI, and invents and develops new technologies for protein expression and production. Dr. Esposito received his BA in Chemistry at La Salle University in Philadelphia, and his Ph.D. in Biochemistry at the Johns Hopkins University Bloomberg School. Dr. Esposito previously worked for Life Technologies, where he helped to develop the Gateway recombinational cloning system.


<<Back to Short Courses